Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seattle Genetics Hoping Its Adcetris Trials Can Do Double Duty

This article was originally published in The Pink Sheet Daily

Executive Summary

Story outside: Trials in other indications can suffice as confirmatory trials for accelerated approval in the relapsed/refractory settings, FDA says during advisory committee review

You may also be interested in...



Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris

Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.

Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris

Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.

Oncology Price Scale Tips Higher: Seattle Genetics Adcetris To Cost Over $100K

Amid record-topping oncology drug prices, yet another high-priced therapy will hit the market, following accelerated approval from FDA.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel